These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 10687428)

  • 1. [Thrombocytopenic thrombotic purpura, HIV, and antiviral therapy].
    Valencia Ortega ME; Gil Aguado A; Lavilla Uriol P; González Lahoz J
    Rev Clin Esp; 1999 Dec; 199(12):859-60. PubMed ID: 10687428
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
    Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study shows three drugs better than two.
    AIDS Alert; 1997 Apr; 12(4):39. PubMed ID: 11364145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of onychomycosis without antifungal therapy after initiation of highly active anti-retroviral therapy (HAART) in an HIV-infected patient.
    Tachikawa N; Yasuoka A; Oka S
    Jpn J Infect Dis; 1999 Dec; 52(6):245-6. PubMed ID: 10738363
    [No Abstract]   [Full Text] [Related]  

  • 5. Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1.
    Launay O; Gérard L; Morand-Joubert L; Flandre P; Guiramand-Hugon S; Joly V; Peytavin G; Certain A; Lévy C; Rivet S; Jacomet C; Aboulker JP; Yéni P;
    Clin Infect Dis; 2002 Nov; 35(9):1096-105. PubMed ID: 12384844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly active antiretroviral therapy: progress and pitfalls.
    Wood LV
    J Pediatr; 1999 Dec; 135(6):655-7. PubMed ID: 10586162
    [No Abstract]   [Full Text] [Related]  

  • 7. ddI + d4T + IDV well tolerated in HIV-infected children.
    AIDS Patient Care STDS; 1997 Oct; 11(5):373. PubMed ID: 11361822
    [No Abstract]   [Full Text] [Related]  

  • 8. Ongoing open-label trials of triple therapy with stavudine and lamivudine or stavudine and didanosine plus nelfinavir.
    Anderson RD
    Antivir Ther; 1998; 3 Suppl 4():63-4. PubMed ID: 10723514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Observational study on the efficacy of the application of two classical regimens of triple antiretroviral therapy].
    Eiros Bouza JM; Ortega Lafont M; Ortiz de Lejarazu R; Bachiller Luque P; de Luis Román DA
    An Med Interna; 2003 May; 20(5):239-42. PubMed ID: 12831297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373.
    Gulick RM; Smeaton LM; D'Aquila RT; Eron JJ; Currier JS; Gerber JG; Acosta E; Sommadossi JP; Tung R; Snyder S; Kuritzkes DR; Murphy RL;
    J Infect Dis; 2001 Mar; 183(5):715-21. PubMed ID: 11181147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial.
    Flandre P; Peytavin G; Meiffredy V; Saidi Y; Descamps D; Delagnes M; Brun-Vézinet F; Raffi F;
    Antivir Ther; 2002 Jun; 7(2):113-21. PubMed ID: 12212923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
    Murphy RL
    Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Thrombotic thrombocytopenic purpura (TTP) mimicking meningoencephalitis].
    Nafil H; Tazi I; Mahmal L
    Rev Neurol (Paris); 2012 Nov; 168(11):873-4. PubMed ID: 22682048
    [No Abstract]   [Full Text] [Related]  

  • 14. [Stavudine and lamivudine. Two new nucleoside analogues efficient against HIV].
    Gerstoft J
    Ugeskr Laeger; 1998 Jan; 160(4):457-61. PubMed ID: 9463266
    [No Abstract]   [Full Text] [Related]  

  • 15. Double protease inhibitor regimens with amprenavir show promise.
    AIDS Patient Care STDS; 1998 Apr; 12(4):317-8. PubMed ID: 11361962
    [No Abstract]   [Full Text] [Related]  

  • 16. Nucleoside combinations for antiretroviral therapy: efficacy of stavudine in combination with either didanosine or lamivudine.
    Fisher M
    AIDS; 1998; 12 Suppl 3():S9-16. PubMed ID: 15168718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lamivudine 300 mg in HIV infection: dose change. Once-a-day dosing.
    Prescrire Int; 2004 Apr; 13(70):54. PubMed ID: 15148972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection.
    Smith D; Berrey MM; Robertson M; Mehrotra D; Markowitz M; Perrin L; Clumeck N; Lazzarin A; Burckhardt B; Weber R; Corey L; Cooper DA
    J Infect Dis; 2000 Sep; 182(3):950-4. PubMed ID: 10950796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Data in from first head-to-head protease inhibitor.
    AIDS Patient Care STDS; 1998 Apr; 12(4):317. PubMed ID: 11361961
    [No Abstract]   [Full Text] [Related]  

  • 20. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.